Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Trial Profile

Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Fulranumab (Primary)
  • Indications Pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 23 May 2016 Planned End Date changed from 1 Feb 2018 to 1 Sep 2016.
    • 23 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2016.
    • 31 Mar 2016 According to a Janssen media release, the company is discontinuing phase 3 development program for fulranumab in osteoarthritis pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top